FDA Grants Clearance to Plus Therapeutics for Innovative Treatment
Plus Therapeutics, Inc. (Nasdaq: PSTV), a pioneering clinical-stage pharmaceutical company, proudly announces the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for REYOBIQ™. This innovative therapy targets pediatric patients battling specific types of brain cancers, including high-grade glioma and ependymoma.
Exciting New Phase 1/2a Clinical Trial
The upcoming Phase 1/2a clinical trial, known as the ReSPECT-PBC trial, has garnered considerable attention as it seeks to explore a groundbreaking radiotherapeutic approach for treating these difficult-to-manage cancers. The trial is backed by a significant $3 million grant from the U.S. Department of Defense, underlining the importance of this research.
Trial Goals and Design
This trial is carefully designed to evaluate the maximum tolerated dose (MTD), safety, and effectiveness of REYOBIQ™ in a targeted age group of pediatric patients aged 6 to 21 years, with the flexibility to include individuals up to 25 years on a case-by-case basis. It aims to enroll 56 patients across two phases, assessing initial tolerability and further efficacy through carefully structured dose escalation.
Details of the Dosage Phases
In the initial phase, an estimated 24 patients will experience a modified dose escalation approach to establish the maximum tolerated dose and the recommended phase 2 dose. Following that, approximately 32 patients, including 12 with ependymoma and 20 with high-grade glioma, will be treated to evaluate efficacy.
REYOBIQ™: A Revolutionary Radiotherapeutic
REYOBIQ™ represents a significant advancement in treatment methodologies by enabling high doses of targeted radiation to directly reach tumor sites while safeguarding surrounding healthy tissues. This innovative approach is designed to surmount the challenges presented by the blood-brain barrier, offering new hope to patients with aggressive tumors where standard treatment options have historically yielded poor outcomes.
Statement from Leadership
Dr. Ashley S. Plant, the principal investigator of the ReSPECT-PBC trial, expressed her enthusiasm about the prospects of REYOBIQ™: "This therapy could transform treatment options available for children with aggressive brain tumors, ultimately improving their chances of recovery and overall quality of life." Marc Hedrick, Plus Therapeutics’ President and CEO, emphasized the importance of this clearance, stating that it builds upon their encouraging efforts observed in clinical trials involving similar adult conditions.
Pediatric Brain Cancer: A Chaotic Landscape
Pediatric high-grade glioma and ependymomas, while rare, remain particularly challenging to treat, presenting with dire survival statistics. With historical five-year survival rates as low as 22%, there is an urgent need for innovative solutions like REYOBIQ™ that can effectively address these aggressive cancers.
Contributions to Existing Research
REYOBIQ™ is not emerging in isolation; it builds on promising data from earlier trials involving adult patients with recurrent glioblastoma. Previous efforts demonstrated favorable responses, and there is optimism surrounding the applicability of these findings to pediatric operations.
Company Commitment to Innovation
Plus Therapeutics remains devoted to developing targeted treatments that prioritize patient safety and efficacy. With established partnerships and a strong developmental pipeline, the company is positioned to make a meaningful impact in the battle against central nervous system cancers.
Frequently Asked Questions
What is the purpose of the ReSPECT-PBC trial?
The ReSPECT-PBC trial aims to assess the safety and efficacy of REYOBIQ™ in treating pediatric patients with challenging brain cancers.
Who will be eligible to participate in the trial?
Pediatric patients aged 6 to 21 years will be eligible, with consideration for those up to 25 years on a case-by-case basis.
How much funding is supporting the clinical trial?
The trial is supported by a generous $3 million grant from the U.S. Department of Defense.
What types of brain tumors are being targeted?
The trial focuses on treating high-grade glioma and ependymoma in pediatric patients.
What distinguishes REYOBIQ™ from conventional therapies?
REYOBIQ™ delivers targeted radiation directly to tumors while minimizing harm to surrounding healthy tissues, offering a promising new option for treatment.
